Drug Profile
ICT 121
Alternative Names: ICT-121Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ImmunoCellular Therapeutics
- Developer Cedars-Sinai Health System; ImmunoCellular Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in USA (Intradermal, Injection)
- 08 May 2019 ImmunoCellular Therapeutics and Unknown company entered into a asset purchase agreement for ICT 107, ICT 140, ICT 121 and stem-to-T-cell research programme preclinical asset
- 13 Aug 2018 Phase I development is ongoing in USA